Navigation Links
Cytos Invites to the Annual Shareholders' Meeting 2013
Date:6/5/2013

ZURICH, June 6, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd ("Cytos") today announced that the Annual Shareholders' Meeting 2013 will take place on Friday, 28 June 2013, at 10 a.m. at Cytos' offices in Schlieren/Zurich (Switzerland). The invitation including the agenda is available for downloading at

http://www.cytos.com/uploads/2013/Cytos_GV_Invitation_FINAL_2013.pdf

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class immune modulator in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com 

This foregoing press release may contain forward-looking statements that include words or phrases such as "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.


'/>"/>
SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
2. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
3. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
4. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
5. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
6. Cardinal Health Foundation Invites Local Non-profit Organizations To Apply For Grants To Prevent Prescription Drug Abuse
7. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
8. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
9. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
10. Heraeus Survey Invites Customers to Share "What they Really Think"
11. Total Therapeutic Management, Inc. invites directors of quality improvement to learn secrets of provider engagement strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental Implants ... ... for Dental Implants in US$ Million. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through 2022. ...
(Date:3/24/2017)... -- FinancialBuzz.com News Commentary  ... According to new data published ... the legal cannabis market is projected to continue to grow ... from the current presidential administration. The report created by Arcview,s ... of growth in this industry are the passage and subsequent ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing ... the product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... that they are now offering treatments for sleep apnea and TMJ at their ... Sleep apnea , specifically the obstructive type, is increasingly being treated at ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
Breaking Medicine News(10 mins):